Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL)

NCT02533700 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT02533700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02533700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL)
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2015
Completion date
December 31, 2020
Enrollment
106 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alk-negative anaplastic large cell lymphoma, angioimmunoblastic t cell lymphoma, enteropathy associated t cell lymphoma, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, not otherwise specified, subcutaneous panniculitis like t cell lymphoma